All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
TCT Meeting 2019 | Salivary zymogen granule protein 16B is a potential salivary biomarker for oral chronic graft-versus-host disease
On 21 February 2019, Jacqueline W. Mays from the National Institutes of Health, Bethesda, MD, USA, presented results on behalf of colleagues of a study evaluating whole saliva for the presence of a diagnostic biomarker profile at first onset of oral chronic graft-versus-host disease (cGvHD) prior to initiation of topical steroid therapy at the 2019 TCT Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR in Houston, Texas, USA.
Patients and methods
- Samples were collected at oral cGvHD onset from NIH protocols: NCT00331968, NCT00520130, or NCT01851382
- Patients had biopsy-proven oral GvHD
- Kruskal-Wallis test was used for protein identification
- Selected proteins were validated by Western blot (WB) in two independent cohorts
- Cohort 1: post-hematopoietic stem cell transplantation (HSCT) patients with (n = 10) and without (n = 10) oral cGvHD
- Cohort 2: post-HSCT patients with (n = 12) and without (n = 12) oral cGvHD
Key findings
- The dataset included 569 confidently-identified proteins, with 77 significantly differentially expressed at the onset of cGvHD
- Zymogen granule protein 16B (ZG16B) was reduced 2-fold in the saliva of post-HSCT patients with oral cGVHD (898.1 ± 371.8 AU) compared with post-HSCT patients without oral cGVHD (1905 ± 598.6 AU) P< 0.05)
- Immunohistochemically (IHC) staining for ZG16B demonstrated a significant decrease in ZB16B protein expression in patient labial salivary gland tissue after oral cGVHD onset
Conclusion
Jacqueline W. Mays concluded that ZG16B is present in lower amounts in unstimulated whole saliva and within the salivary gland acinar units at oral cGvHD onset. Reduction in the ZG16B protein may indicate cGvHD activity as well as potentially causing salivary gland damage. Dr. Mays added that further investigation in a larger cohort is required to assess whether saliva can be used to identify a diagnostic biomarker profile for oral cGvHD.
References